跳至主要内容
临床试验/JPRN-UMIN000019250
JPRN-UMIN000019250已完成未知

Evaluation of long-term anti-IgE antibody therapy in the patients with wheat allergy - Long-term anti-IgE antibody therapy

Shimane University Hospital0 个研究点目标入组 20 人开始时间: 2015年10月10日最近更新:
适应症
相关药物

试验速览

阶段
未知
状态
已完成
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Patients who have hypersensitivity to ingredients of Omalizumab (Novartis Pharma, Japan). 2. Patients who receive immunosuppressive drugs. 3. Patients with decompensated liver cirrhosis. 4. Patients with severe kidney disease; more than 2.0mg/dL of serum creatinine level within 4 weeks prior to the entry. 5. Patients with liver disease, psychiatric disorder, convulsive seizure and seizure disorder, cardiovascular disease, abnormal hemoglobin disease, hemophilia, and autoimmune disease. 6. Pregnant women, breast-feeding women, and women suspected of being pregnant. 7. Patients ineligible for the clinical trial at a physician's discretion.

研究者

相似试验